Acute and chronic arecoline: Effects on a scopolamine-induced deficit in complex maze learning

Pharmacology Biochemistry and Behavior

Volumn 53, Issue 3, 1996, Pages 713-721

  Bratt, Alison M ^a,b   Kelly, M Elizabeth ^a   Domeney, Annette M ^a   Naylor, Robert J ^a   Costall, Brenda ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b University of Memphis   (United States)

Author keywords

Arecoline; Cholinergic system; Continuous drug infusion; Memory and learning; Osmotic minipumps; Scopolamine; Stone maze

Indexed keywords

ARECOLINE; METHYLSCOPOLAMINE; MUSCARINIC AGENT; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG POTENTIATION; ERROR; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNING DISORDER; MALE; MAZE TEST; MEMORY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT;

EID: 0029915392     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02074-8     Document Type: Article

References (66)

1. 3 antagonist on cognition in rodents and primates. Pharmacol. Biochem. Behav. 35:955-962; 1990.
2. Barnes, J. C.; Roberts, F. F. Central effects of muscarinic agonists and antagonists on hippocampal theta rhythm and blood pressure in the anaesthetised rat. Eur. J. Pharmacol. 195:233-240; 1991.
3. Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of memory dysfunction. Science 217:408-417; 1982.
4. Beatty, W. W.; Bierley, R. A. Scopolamine impairs encoding and retrieval of spatial working memory in rats. Physiol. Psychol. 14(3&4):82-86; 1986.
5. Becker, R. E.; Giacobini, E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological and therapeutic aspects. Drug Dev. Res. 12:163-195; 1988.
6. Blokland, A.; Honig, W.; Raaijmakers, G. M. Effects of intrahippocampal scopolamine injections in a repeated spatial acquisition task in the rat. Psychopharmacol. 109:373-376; 1992.
7. Bowen, D. M.; Spillane, J. A.; Curzon, G.; Meir-Rhoe, W.; White, P.; Goodhardt, M. J.; Iwangoff, P.; Davson, A. M. Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet Jan 6:11-14; 1979.
8. Bratt, A. M.; Kelly, M. E.; Domeney, A. M.; Naylor, R. J.; Costall, B. Aged Stone maze impaired rats exhibit reduced striatal muscarinic receptor densities. Neuroreport 5:2678-2682; 1994.
9. Bratt, A. M.; Kelly, M. E.; Domeney, A. M.; Naylor, R. J.; Costall, B. Ondansetron fails to attenuate a scopolamine-induced deficit in a Stone maze task. Neuroreport 5:1921-1924; 1994.
10. Brazell, C.; Ward, P. C.; Lines, C. R.; Traub, M. The scopolamine model of dementia: Chronic transdermal administration. J. Psychopharmacology 3(2):76-82; 1989.
11. Broks, P.; Preston, G. C.; Traub, M.; Poppleton, P.; Ward, C.; Stahl, S. M. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26(5):685-700; 1988.
12. Buresova, O.; Bures, J. Radial maze as a tool for assessing the effect of drugs on the working memory of rats. Psychopharmacology 77:268-271; 1982.
13. Bymaster, F. P.; Heath, I.; Hendrix, J. C; Shannon, H. E. Comparative behavioural and neurochemical activities of cholinergic antagonists in rats. J. Pharmacol. Exp. Ther. 267(1):16-24; 1993.
14. Cheal, M. Scopolamine disrupts maintenance of attention rather than memory processes. Behav. Neural Biol. 33:163-187; 1981.
15. Christie, J. E.; Shering, A.; Ferguson, J.; Glen, A. I. M. Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia. Br. J. Psychiat. 138:46-50; 1981.
16. Davidson, M.; Stern, R. G.; Bierer, L. M.; Horvath, T. B.; Zemishlani, Z.; Markofsky, R.; Mohs, R. C. Cholinergic strategies in the treatment of Alzheimer's disease. Acta. Psychiat. Scand. 366(83):47-51; 1991.
17. Day, J.; Damsma, G.; Fibiger, H. C. Cholinergic activity in the rat hippocampus, cortex and striatum correlates with locomotor activity: An in vivo microdialysis study. Pharmacol. Biochem. Behav. 38:723-729; 1991.
18. Decker, M. W. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res. Rev. 12:423-438; 1987.
19. Decker, M. W.; McGaugh, J. L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7:151-168; 1991.
20. Dolezal, V.; Wecker, L. Muscarinic receptor blockade increases basal acetylcholine release from striatal slices. J. Pharmacol. Exp. Ther. 252(2):739-743; 1990.
21. Fibiger, H. C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. 14(6): 220-234; 1991.
22. Goodrick, C. L. Problem solving and age: A critique of rodent research. In: Sprott, R. L., ed. Age, learning ability and intelligence. Van Nostrand Reinhold Co.; 1980:5-25.
23. Gray, J. A.; Enz, A.; Spiegel, R. Muscarinic agonists for senile dementia: past experience and future trends. Trends Pharmacol. Sci. Supplement:85-88; 1989.
24. Harbaugh, S. T.; Roberts, D. W.; Coombs, D. W.; Saunders, R. L.; Reeder, T. M. Preliminary report: Intracranial drug infusion in patients with Alzheimer's disease. Neurosurgery 15(4):514-518; 1984.
25. Hepler, D. J.; Wenk, G. L.; Cribbs, B. L.; Olton, D. S.; Coyle, J. T. Memory impairments following basal forebrain lesions. Brain Res. 346:8-14; 1985.
26. Hoss, W.; Messer Jr.; W. S.; Monsma Jr.; F. J.; Miller, M. D.; Ellerbrock, B. R.; Scranton, T.; Ghodsi-Hovespian, S.; Price, M. A.; Balan, S.; Mazloum, Z.; Bohnett, M. Biochemical and behavioural evidence for muscarinic autoreceptors in the CNS. Brain Res. 517:195-201; 1990.
27. Ingram, D. K. Complex maze learning in rodents, progress and potential for modelling age-related memory dysfunction. In: Goldstein, A. L.; ed. Biomedical advances in aging. New York: Plenum Press; 1990:451-467.
28. Kametani, H.; Bresnahan, E. L.; Chachich, M. E.; Spangler, E. L.; Ingram, D. K. Comparison of retention performance between young rats with fimbria-fornix lesions and aged rats in a 14-unit T-maze. Behav. Brain Res. 35:253-263; 1989.
29. Kerenyi, S. Z; Hargraves, S. L. Premature excess release from the Alzet osmotic minipump. Pharmacol. Biochem. Behav. 27:199-201; 1987.
30. Krogsgaard-Larsen, O.; Falch, E.; Sauerberg, P.; Freedman, S. B.; Lembol, H. L.; Maier, E. Bio isoteres of arecoline as novel CNS-active muscarinic agonists. Trends Pharmacol. Sci. Supplement:69-73; 1988.
31. Kumar, V.; Calache, M. Treatment of Alzheimer's disease with cholinergic drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 29(1): 23-27; 1991.
32. Lamberty, Y.; Gower, A. J. Cholinergic modulation of spatial learning in mice in a Morris-type water maze. Arch. Int. Pharmacodyn. 309:5-19; 1991.
33. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117; 1985.
34. Messer, W. S., Jr.; Ellerbrock, B.; Price, M.; Hoss, W. Autoradiographic analyses of agonist binding to muscarinic receptor subtypes. Biochem. Pharmacol. 38:837-850; 1989.
35. Mohs, R. C.; Davis, K. L.; Tinkelberg, J. R.; Hollister, K. E. Choline chloride effects on memory in the elderly. Neurobiol. Aging 1:21-25; 1980.
36. Nordstrom, O.; Bartfai, T. Muscarinic autoreceptor regulates acetylcholine release in rat hippocampus: in vitro evidence. Acta Physiol. Scand. 108:347-353; 1980.
37. 1 muscarinic receptors impairs working memory performance of rats. Brain Res. 650:260-266; 1994.
38. Okaichi, H.; Oshima, Y.; Jarrard, L. E. Scopolamine impairs both working and reference memory in rats: A replication and extension. Pharmacol. Biochem. Behav. 34:599-602; 1989.
39. Olton, D. S. Dementia: Animal models of the cognitive impairments following damage to the basal forebrain cholinergic system. Brain Res. Bull. 25:499-502; 1990.
40. Palacios, J. M.; Boddeke, H. W. G. M.; Pombo-Villar, E. Cholinergic neuropharmacology:an update. Acta Psychiat. Scand. 366(83):27-33; 1991.
41. Perry, E. K.; Perry, R. H.; Gibson, P. H.; Blessed, G.; Tomlinson, B. E. A cholinergic connection between normal ageing and senile dementia in human hippocampus. Neurosci. Lett. 6:85-89; 1977.
42. 1 muscarinic receptors. J. Pharmacol. Exp. Ther. 248(3):974-978; 1988.
43. Preston, G. C.; Brazell, C.; Ward, C.; Broks, P.; Traub, M.; Stahl, S. M. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. J. Psychopharmacol. 2(2):67-79; 1988.
44. Price, D. L.; Cork, L. C.; Struble, R. G.; Whitehouse, P. J.; Kitt, C. A.; Walker, L. C. The functional organisation of the basal forebrain cholinergic system in primates and the role of this system in Alzheimer's disease. Ann. N. Y. Acad. Sci. 444:287-295; 1985.
45. Quirion, R.; Aubert, I.; Lapchak, P. A.; Schaum, R. P.; Teolis, S.; Gauthier, S.; Araujo, D. M. Muscarinic receptor subtypes in human neurodegenerative disorders: Focus on Alzheimer's disease. Trends Pharmacol. Sci. supplement:80-84; 1989.
46. Raffaele, K. C.; Berardi, A.; Asthana, S.; Morris, P.; Haxby, J. V.; Soncrant, T. T. Effects of long term continuous infusion of the muscarinic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol. Bull. 27(3):315-319; 1991.
47. Ridley, R. M.; Murray, T. K.; Johnson, J. A.; Baker, H. F. Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: Modification by cholinergic drugs. Brain Res. 376:108-116; 1986.
48. Rupniak, N. M. J.; Steventon, M. J.; Field, M. J.; Jennings, C. A.; Iversen, S. D. Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 99:189-195; 1989.
49. Rusted, J. M.; Warburton, D. M. The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology 96:145-152; 1988.
50. Safer, D. J.; Allen, R. P. The central effects of scopolamine in man. Biol. Psychiat. 3:347-355; 1971.
51. Sarter, M.; Bruno, J. P.; Dudenchenko, P. Activating the damaged basal forebrain cholinergic system: tonic stimulation vs. signal amplification. Psychopharmacology 101:1-17; 1990.
52. Shannon, H. E.; Bemis, K. G.; Hendrix, J. C.; Ward, J. S. Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alteration performance in rats. J. Pharmacol. Exp. Ther. 255(3):1071-1077; 1990.
53. Sims, N. R.; Bowen, D. M.; Smith, C. C. T.; Flack, R. H. A.; Davison, A. N.; Snowdon, J. S.; Neary, D. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1:333-335; 1980.
54. Soncrant, T. T.; Holloway, H. W.; Greig, N. H; Rapoport, S. I. Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats. Brain Res. 487:255-266; 1989.
55. Spangler, E. L.; Cachich, M. E.; Ingram, D. K. Scopolamine in rats impairs acquisition but not retention in a 14-unit T-maze. Pharmacol. Biochem. Behav. 30:949-955; 1988.
56. Spencer, D. G., Jr.; Lal, H. Effects of anticholinergic drugs on learning and memory. Drug Devel. Res. 3:489-502; 1983.
57. Spencer, D. G.; Van Rooijen, L. A. A.; Horvath E.; Dompert, W.; Traber, J. Neurochemical and behavioural effects of muscarinic acetylcholine receptor agonists. Trends Pharmacol. Sci. Supplement:61-68; 1988.
58. Stern, Y.; Sano, M.; Mayeux, R. Long term adminstration of oral physostigmine in Alzheimer's disease. Neurology, 38:1837-1841; 1988.
59. Stone, C. P. The age factor in animal learning II: Rats on a multiple light discrimination box and a difficult maze. Genet. Psyc. Mono. 6(1):125-202; 1929.
60. Tariot, P. N.; Cohen, R. M.; Welkowitz, J. A.; Sunderland, T.; Newhouse, P. A.; Murphey, D. L.; Weingartner, H. Multiple dose arecoline infusions in Alzheimer's disease. Arch. Gen. Psychiat. 45:901-905; 1988.
61. Tonnaer, J. A. M. D.; Ernste, B. H. W.; Wester, J.; Kelder, K. Cholinergic innervation and topographical organisation of muscarinic binding sites in rat brain: A comparitive autoradiographic study. J. Chem. Neuroanat. 1:95-110; 1988.
62. Vogt, B. A. Localisation of cortical muscarinic receptor subtypes. Trends Pharmacol. Sci. Supplement:49-53; 1988.
63. Whishaw, I. Q. Cholinergic receptor blockade in the rat impairs locale but not taxon strategies for place navigation in a swimming pool. Behav. Neurosci. 99:979-1005; 1988.
64. Whishaw, I. Q.; Tomie, J. A. Cholinergic receptor blockade produces impairments in a sensorimotor subsystem for place navigation in the rat: Evidence from sensory, motor, and acquisition tests in a swimming pool. Behav. Neurosci. 101:603-616; 1987.
65. Whitehouse, P.; Price, D.; Struble, R.; Clark, A.; Coyle, J.; Delong, M. Alzheimer's disease and senile dementia: loss of neurones in the basal forebrain. Science 215:1237-1239; 1982.
66. Winer, B. J. Statistical principles in experimental design. New York: McGraw Hill; 1971.